PharMerica Comments on FTC Decision to Block Omnicare's Hostile Tender Offer

PharMerica Corporation (NYSE: PMC) today commented on the decision by the Federal Trade Commission to sue to block Omnicare's (NYSE: OCR) unsolicited offer to acquire PharMerica.

“We are pleased the FTC has made a prompt decision to resolve the competitive issues surrounding Omnicare's attempted hostile takeover of PharMerica Corporation,” said Gregory S. Weishar, PharMerica Chief Executive Officer. “As we have said from the beginning, we believed antitrust clearance would be difficult to achieve and, with that belief now confirmed, we hope that Omnicare will end its hostile pursuit of PharMerica.

"We believe PharMerica is well positioned to deliver outstanding value for customers and stockholders as we pursue our strategic initiatives and head into the accelerating wave of generic drug conversions in 2012 and beyond.”